Dr. Howard S. Hochster
Claim this profileRutgers Cancer Institute of New Jersey
Expert in Colorectal Cancer
Studies Colon Cancer
17 reported clinical trials
37 drugs studied
About Howard S. Hochster
Education:
- Obtained undergraduate and graduate degrees from Yale University.
- Earned an MD from Yale School of Medicine.
Experience:
- Completed internship and residency at Bellevue Hospital/New York University School of Medicine.
- Served over two decades in leadership roles at the New York University Cancer Institute, including leading the Office of Clinical Trials and Developmental Therapeutics.
- Holds faculty positions at Yale Cancer Center and Yale School of Medicine, including professor of medicine and associate director for clinical sciences.
- Currently, Associate Director for Clinical Research and Director of GI Oncology at Rutgers Cancer Institute, and Director of Oncology Research at RWJBarnabas Health.
Area of expertise
1Colorectal Cancer
Global LeaderStage IV
Stage III
BRAF negative
2Colon Cancer
Stage IV
Stage III
BRAF negative
Affiliated Hospitals
Clinical Trials Howard S. Hochster is currently running
Chemotherapy + Bevacizumab + Atezolizumab
for Colorectal Cancer
This phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab may stop or slow colorectal cancer by blocking the growth of new blood vessels necessary for tumor growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy, bevacizumab, and atezolizumab may work better in treating patients with colorectal cancer.
Recruiting2 awards Phase 31 criteria
Chemotherapy + Bevacizumab
for Metastatic Colorectal Cancer
This study is to evaluate the disease control rate and time to progression of the sequential combination of oxaliplatin with an alternative anti-metabolite Trifluridine/tipiracil hydrochloride mixture, TAS-102,(TAS-OX) as well as irinotecan in combination with TAS-102 oxaliplatin(TAS-OX) + Bevacizumab in late-line metastatic colorectal cancer (mCRC)
Recruiting1 award Phase 2
More about Howard S. Hochster
Clinical Trial Related5 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Howard S. Hochster has experience with
- Oxaliplatin
- Bevacizumab
- Atezolizumab
- Irinotecan
- TAS-102
- Cetuximab
Breakdown of trials Howard S. Hochster has run
Colorectal Cancer
Colon Cancer
Skin Cancer
Gastroesophageal Junction Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Howard S. Hochster specialize in?
Howard S. Hochster focuses on Colorectal Cancer and Colon Cancer. In particular, much of their work with Colorectal Cancer has involved Stage IV patients, or patients who are Stage III.
Is Howard S. Hochster currently recruiting for clinical trials?
Yes, Howard S. Hochster is currently recruiting for 6 clinical trials in New Brunswick New Jersey. If you're interested in participating, you should apply.
Are there any treatments that Howard S. Hochster has studied deeply?
Yes, Howard S. Hochster has studied treatments such as Oxaliplatin, Bevacizumab, Atezolizumab.
What is the best way to schedule an appointment with Howard S. Hochster?
Apply for one of the trials that Howard S. Hochster is conducting.
What is the office address of Howard S. Hochster?
The office of Howard S. Hochster is located at: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey 08903 United States. This is the address for their practice at the Rutgers Cancer Institute of New Jersey.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.